Preliminary study of buprenorphine and bupropion for opioid-dependent smokers

American Journal on Addictions

Volumn 17, Issue 4, 2008, Pages 287-292

  Mooney, Marc E ^a   Poling, James ^b   Gonzalez, Gerardo ^b   Gonsai, Kishor ^b   Kosten, Thomas ^c   Sofuoglu, Mehmet ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; COCAINE; ILLICIT DRUG; NALOXONE; NICOTINE; OPIATE; PLACEBO;

ADULT; AGED; AGITATION; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERVENTION STUDY; MALE; OPIATE ADDICTION; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; SIDE EFFECT; SMOKING CESSATION; SURVIVAL; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPRENORPHINE; BUPROPION; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SMOKING; SMOKING CESSATION; TOKEN ECONOMY;

EID: 46849093627     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802138814     Document Type: Article

References (39)

1. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14:106-123.
2. McCool RM, Richter KP, Choi WS. Benefits of and barriers to providing smoking treatment in methadone clinics: Findings from a national study. Am J Addict. 2005;14:358-366.
3. Pomerleau OF. Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology. 1998;23:115-130.
4. Mello NK, Lukas SE, Mendelson JH. Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl). 1985;86:417-425.
5. Mello NK, Mendelson JH, Sellers ML, Kuehnle JC. Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berl). 1980;67:45-52.
6. Richter KP, Hamilton AK, Hall S, Catley D, Cox LS, Grobe J. Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007;15:144-153.
7. Schmitz JM, Grabowski J, Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 1994;34:237-242.
8. Story J, Stark MJ. Treating cigarette smoking in methadone maintenance clients. J Psychoactive Drugs. 1991;23:203-215.
9. Spiga R, Schmitz J, Day J II. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 1998;50:157-165.
10. Gilbert DG, Meliska CJ, Williams CL, Jensen RA. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology (Berl). 1992;106:275-281.
11. Meliska CJ, Gilbert DG. Hormonal and subjective effects of smoking the first five cigarettes of the day: A comparison in males and females. Pharmacol Biochem Behav. 1991;40:229-235.
12. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl). 1983;81:61-67.
13. Seyler LE Jr., Pomerleau OF, Fertig JB, Hunt D, Parker K. Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav. 1986;24:159-162.
14. Stein MD, Weinstock MC, Herman DS, Anderson BJ, Anthony JL, Niaura R. A smoking cessation intervention for the methadone-maintained. Addiction. 2006;101:599-607.
15. Richter KP, McCool RM, Catley D, Hall M, Ahluwalia JS. Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients. J Addict Dis. 2005;24:79-90.
16. Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction. 2002;97:1317-1328.
17. Shoptaw S, Jarvik ME, Ling W, Rawson RA. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addict Behav. 1996;21:409-412.
18. Boothby LA, Doering PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007;64:266-272.
19. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003:CD002207.
20. Margolin A, Kosten TR, Avants SK, et al. Amulticenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 1995;40:125-131.
21. Margolin A, Kosten T, Petrakis I, Avants SK, Kosten T. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch Gen Psychiatry. 1991;48:87.
22. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63:219-228.
23. Poling J, Pruzinsky R, Kosten TR, et al. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007;16:187-194.
24. Carroll KM, Kosten TR, Rounsaville BJ. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004;75:123-134.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID -I / P, Version 2.0). New York: Biometric Research Department; 1995.
27. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
28. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991;86:1119-1127.
29. Aickin M. A program for balancing the allocation of subjects to treatment in a clinical trial. Computers and Biomedical Research, an International Journal 1982;15:519-524.
30. Benowitz NL, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.
31. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294.
32. Bradley BP, Gossop M, Phillips GT, Legarda JJ. The development of an opiate withdrawal scale (OWS). British Journal of Addiction 1987;82:1139-1142.
33. The SAS System for Windows [computer program]. Version 9.13. Cary, NC: SAS Institute Inc.; 2006.
34. Javors MA, Hatch JP, Lamb RJ. Cut-off levels for breath carbonmonoxide as a marker for cigarette smoking. Addiction. 2005;100:159-167.
35. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002;62 (Suppl. 2):45-52.
36. Stein MD, Anderson BJ, Niaura R. Nicotine replacement therapy - patterns of use after a quit attempt among methadone-maintained smokers. J Gen Intern Med. 2006;21:753-757.
37. Peirce JM, Petry NM, Stitzer ML, et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry. 2006;63:201-208.
38. Richter KP. Good and bad times for treating cigarette smoking in drug treatment. J Psychoactive Drugs. 2006;38:311-315.
39. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.